-
1 Comment
Extrawell Pharmaceutical Holdings Limited is currently in a long term downtrend where the price is trading 13.3% below its 200 day moving average.
From a valuation standpoint, the stock is 93.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Extrawell Pharmaceutical Holdings Limited's total revenue sank by 13.0% to $19M since the same quarter in the previous year.
Its net income has increased by 30.1% to $21M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.7% to $-3M since the same quarter in the previous year.
Based on the above factors, Extrawell Pharmaceutical Holdings Limited gets an overall score of 3/5.
| ISIN | BMG3285Q1134 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | HK |
| CurrencyCode | HKD |
| Market Cap | 115M |
|---|---|
| PE Ratio | 0.69 |
| Target Price | None |
| Beta | 0.06 |
| Dividend Yield | None |
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China and Hong Kong. It operates through Manufacturing, Trading, and Gene Development segments. The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. It also involves in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure. In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; and property investment business. Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0858.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
